Skip to content

Observation of the therapeutic effect of silver needle heat conduction therapy on early plantar fasciitis, a prospective, double-blind, multi-center, randomized controlled trial

Observation of the therapeutic effect of silver needle heat conduction therapy on early heel pain, a prospective, double-blind, multi-center, randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043581
Enrollment
Unknown
Registered
2021-02-23
Start date
2021-03-08
Completion date
Unknown
Last updated
2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plantar Fasciitis

Interventions

Test:silver needle heat conduction therapy
Control:silver needle therapy

Sponsors

the Affiliated Hospital of Qingdao Univeristy
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The diagnosis of plantar fasciitis is made by a pain expert with more than ten years of professional experience. 18-60 years old, duration 1-3 months with heel swelling; no local hormone and or local anesthetic injection, surgical operation and other invasive operations; VAS score in the morning, first step heel pain >=5 points or proceed Heel pain during daily activities >5 points; Roles and Maudsley score is acceptable/poor; receive hot compress, ice compress, massage, oral NSAIDs for at least 3 days; if appropriate, magnetic resonance imaging (MRI), nerve conduction velocity/muscle Electrographic examination or other diagnostic tests to confirm plantar fasciitis or rule out other diagnoses.

Exclusion criteria

Exclusion criteria: History of active infection or chronic infection in the treatment area, systemic inflammatory disease, nerve or vascular insufficiency, nerve compression symptoms, coagulation disorders, bilateral plantar pain, history of foot surgery, pregnancy, diabetes, tumors, long-term opioids History of taking drugs or corticosteroids, alcohol abuse, inability to communicate normally, or mental illness

Design outcomes

Secondary

MeasureTime frame
reduction of VAS;satisfaction;

Primary

MeasureTime frame
VAS;Roles and Maudsley score;

Countries

China

Contacts

Public ContactChao Meng

the Affiliated Hospital of Qingdao University

mengchao1119@hotmail.com+86 18661808786

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026